Asymptomatic COVID-19 and structural changes in the brain

Abstract

Aims: Neurological symptoms are the most prevalent extrapulmonary complications of coronavirus disease 2019 (COVID-19). In this context, the objective of this study is to assess the brain magnetic resonance imaging (MRI) parameters of asymptomatic COVID-19 individuals one year after diagnosed with COVID-19 in comparison with healthy control subjects. Methods: The population of this prospective study consisted of individuals who have not developed olfactory impairment or other complications within one year after diagnosed with COVID-19. For the study, 8 male, 25 female, 4 male and 23 female individuals were accepted for PCG and CG, respectively, according to the inclusion and exclusion criteria. The mean age was found to be 37.75±11.56 and 37.11±10.67, respectively. All participants included in the study underwent olfactory sulcus (OS) depth, olfactory bulb (OB) volume, hippocampal sclerosis (HS), insular gyrus area, and corpus amygdala area measurements. Results: The bilateral OB volume, insular gyrus area and corpus amygdala area were significantly lower in the post-COVID-19 group (PCG) than in the control group (CG) (p<0.05). On the other hand, the bilateral OS depth was significantly higher in PCG than in CG (p<0.05). In the PCG, the insular gyrus area and corpus amygdala area values of the right side were significantly higher than those of the left side (p<0.05). In addition, bilateral HS was detected in five patients in the PCG, right-sided HS in two patients, and left-sided HS in one patient. Conclusion: The findings of this study have shown that COVID-19 infection, albeit asymptomatic, can trigger neurodegeneration. We believe that in the future COVID-19 infection will play a role in the etiopathogenesis of many neurodegenerative diseases.

Keywords

• Olfactory bulb
• insular cortex
• hippocampal sclerosis
• COVID-19
• amygdala
• prefrontal cortex

References

1. Desai AD, Lavelle M, Boursiquot BC. et al. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2022; 322(1):C1–C11. doi.org/10.1152/ajpcell.00375.2021
2. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
3. Seyed Alinaghi S, Afsahi AM, MohsseniPour M, et al. Late complications of COVID-19; a systematic review of current evidence. Arch Acad Emerg Med. 2021;9(1):e14. doi:10.22037/aaem.v9i1.1058
4. ACTT-1 Study Group., Remdesivir for the treatment of Covid-19: final report. N Engl J Med. 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764
5. Ogut E, Armagan K. evaluation of the potential impact of medical ozone therapy on COVID-19: a review study. Ozone: Science & Engineering. 2022;45(3):213-231. doi:10.1080/01919512.2022.2065242
6. Zawilska JB, Kuczyńska K. Psychiatric and neurological complications of long COVID. J Psychiatr Res. 2022;156:349-360. doi: 10.1016/j.jpsychires.2022.10.045
7. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-1032. doi:10.1038/s41591-020-0968-3
8. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280. doi: 10.1016/j.cell.2020.02.052

9. Qi F, Qian S, Zhang S, et al. Single-cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526(1):135-140. doi:10. 1016/j.bbrc.2020.03.044
10. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016-1035. doi:10.1016/j. cell.2020.04.035
11. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
12. Ehrenfeld M, Tincani A, Andreoli L, et al. COVID-19 and autoimmunity. Autoimmun Rev. 2020;19(8):102597. doi:10.1016/j.autrev.2020.102597
13. Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324(6):603-605. doi:10.1001/jama. 2020.12603
14. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. doi:10.1016/S0140-6736(20)32656-8
15. Generoso JS, Barichello de Quevedo JL, Cattani M, et al. Neurobiology of COVID-19: how can the virus affect the brain? Braz J Psychiatry. 2021;43(6):650-664. doi: 10.1590/1516-4446-2020-1488
16. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767-783.
17. Winkler AS, Knauss S, Schmutzhard E, et al. A call for a global COVID-19 Neuro Research Coalition. Lancet Neurol. 2020;19(6):482-484.
18. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19. Neurol. 2020;95(8):e1060-e1070.
19. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418.
20. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697-707.
21. Crunfli F, Carregari VC, Veras FP, et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci. 2022;119(35):e2200960119. doi: 10.1073/ pnas.2200960119
22. Hugon J, Msika EF, Queneau M, et al. Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. J Neurol. 2022;269(1):44-46.
23. Doğan A, Burulday V, Alpua M. İdiyopatik Parkinson hastalarında olfaktör bulbus volüm ve olfaktör sulkus derinliğinin manyetik rezonans görüntüleme ile değerlendirilmesi. Kırıkkale Üni Tıp Fak Derg. 2019;21(1):22-27. doi:10.24938/kutfd.429018
24. Altmann J. Autoradiographic and histological studies of postnatal neurogenesis. IV. cell proliferation and migration in the anterior forebrain, with special reference to persisting neurogenesis in the olfactory bulb. J Comp Neurol. 1969;137(4):433-457.
25. Graziadei PPC, Graziadei GM. Neurogenesis and neuronregeneration in the olfactory system of mammals. III. deafferentation and reinnervation of the olfactory bulb following section of the fila olfactoria in rat. J Neurocytol. 1980;9(2):145-162.
26. Takahashi T, Ota M, Numata Y, et al. Relationships between the Fear of COVID-19 Scale and regional brain atrophy in mild cognitive impairment. Acta Neuropsychiatrica. 2022;34(3):153-162.
27. Rebsamen M, Friedli C, Radojewski P, et al. Multiple sclerosis as a model to investigate SARS-CoV-2 effect on brain atrophy. CNS Neurosci Ther. 2023;29(2):538-543. doi: 10.1111/cns.14050
28. Jobin B, Boller B, Frasnelli J. Volumetry of olfactory structures in mild cognitive impairment and Alzheimer’s disease: a systematic review and a meta‐analysis. Brain Sci. 2021;11(8):6-13. doi: 10.3390/brainsci11081010
29. Al-Otaibi M, Lessard-Beaudoin M, Castellano CA, et al. Volumetric MRI demonstrates atrophy of the olfactory cortex in AD. Curr Alzheimer Res. 2021;17(10):904-915.
30. Najt P, Richards HL, Fortune DG. Brain imaging in patients with COVID-19: a systematic review. Brain Behav Immun Health. 2021;16:100290. doi: 10.1016/j.bbih.2021.100290
31. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18-22. doi: 10.1016/j.bbi.2020. 03.031
32. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients–an MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25:100484. doi: 10.1016/j.eclinm.2020.100484
33. Rahman A, Tabassum T, Araf Y, et al. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol Rep. 2021;48(4):3863-3869. doi: 10.1007/s11033-021-06358-1
34. Ahmed M, Roy S, Iktidar MA, et al. Post-COVID-19 memory complaints: prevalence and associated factors. Neurología. 2022. doi: 10.1016/j.nrl.2022.03.007
35. Mahajan A, Mason GF. A sobering addition to the literature on COVID-19 and the brain. J Clin Invest. 2021;131(8):e148376. doi: 10.1172/JCI148376
36. Liu X, Yan W, Lu T, Han Y, Lu L. Longitudinal abnormalities in brain structure in COVID-19 patients. Neurosci Bull. 2022;38(12):1608-1612. doi: 10.1007/s12264-022-00913-x
37. Shan D, Li S, Xu R, et al. Post-COVID-19 human memory impairment: a PRISMA-based systematic review of evidence from brain imaging studies. Front Aging Neurosci. 2022;14:1077384. doi: 10.3389/fnagi.2022.1077384.
38. Cecchetti G, Agosta F, Canu E, et al. Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. J Neurol. 2022;269(7):3400-3412. doi: 10.1007/s00415-022-11047-5
39. Ermis U, Rust MI, Bungenberg J, et al. Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurol Res Pract. 2021;3(1):1-12. doi: 10.1186/s42466-021-00116-1
40. Hadad R, Khoury J, Stanger C, et al. Cognitive dysfunction following COVID-19 infection. J Neurovirol. 2022;28(3):430-437. doi: 10.1007/s13365-022-01079-y
41. Meyer PT, Hellwig S, Blazhenets G, et al. Molecular imaging findings on acute and long-term effects of COVID-19 on the brain: a systematic review. J Nucl Med. 2022;63(7):971-980. doi: 10.2967/jnumed.121.263085
42. Bungenberg J, Humkamp K, Hohenfeld C, et al. Long COVID-19: objectifying most self-reported neurological symptoms. Annal Clin Transl Neurol. 2022;9(2):141-154. doi: 10.1002/acn3.51496
43. Newhouse A, Kritzer MD, Eryilmaz H, et al. Neurocircuitry hypothesis and clinical experience treating neuropsychiatric symptoms of post acute sequelae of SARS-CoV-2 (PASC). J Acad Consult Liaison Psychiatry. 2022;63(6):619-627. doi: 10.1016/j.jaclp.2022. 08.007
44. Tian T, Wu J, Chen T, et al. Long-term follow-up of dynamic brain changes in patients recovered from COVID-19 without neurological manifestations. JCI Insight. 2022;7(4):e155827. doi: 10.1172/jci.insight.155827
45. Fernández-Castañeda A, Lu P, Geraghty AC, et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. BioRxiv. 2022:2022.01.07.475453. doi: 10.1101/2022.01.07.475453
46. Li C, Liu J, Lin J. et al. COVID-19 and risk of neurodegenerative disorders: a Mendelian randomization study. Transl Psychiatry. 2022;12(1):283. doi.org/10.1038/s41398-022-02052-3
47. Rahmati M, Yon DK, Lee SW, et al. New-onset neurodegenerative diseases as long-term sequelae of SARS-CoV-2 infection: a systematic review and meta-analysis. J Med Virol. 2023;95(7):e28909. doi: 10.1002/jmv.28909.
48. Leng A, Shah M, Ahmad SA, et al. Pathogenesis underlying neurological manifestations of long COVID syndrome and potential therapeutics. Cells. 2023;12(5):816. doi.org/10.3390/cells 12050816